Cytarabine (Ara-C)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-CYTARABINE |
|---|---|
| Type | Drug |
| Aliases | ACRAra-CCytarabineCytosarЦитарабін |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-AML DIS-B-ALL DIS-BURKITT DIS-CML DIS-MCL DIS-PCNSL DIS-T-ALL |
| Sources | SRC-NCCN-AML-2025 SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Pyrimidine antimetabolite |
|---|---|
| Mechanism | Phosphorylated intracellularly to ara-CTP, incorporated into DNA, inhibits DNA polymerase, terminates chain elongation. Cell-cycle S-phase specific. Backbone of AML induction; high-dose for consolidation + CNS prophylaxis (crosses BBB at HD). |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Severe myelosuppression
- Cerebellar toxicity at HiDAC (dose-related, age >50 risk)
- Conjunctivitis with HiDAC (mandatory steroid eye drops prophylaxis)
Notes
Used in: AML induction (7+3), AML consolidation (HiDAC), MCL intensive (R-DHAP / R-DHAOx for fit transplant-eligible), Burkitt (CODOX-M/IVAC), CNS prophylaxis IT. HiDAC requires careful elderly dose selection (1.5 g/m² instead of 3 g/m² over 65) + eye drops + neurologic exam pre each dose.
Used By
Regimens
REG-AAML1031-PEDIATRIC- AAML1031-style induction (Cytarabine + Daunorubicin + Etoposide, pediatric AML 1L)REG-ALLOHCT-CML-ADVANCED- Allogeneic hematopoietic cell transplant for CML blast crisis OR multi-TKI failureREG-AML-7-3- 7+3 Induction (cytarabine + daunorubicin/idarubicin) ± midostaurinREG-AML-7-3-GO- 7+3 + fractionated gemtuzumab ozogamicin (CD33+ AML, 1L; ALFA-0701)REG-CODOX-M-IVAC- CODOX-M / IVAC alternating × 4 (Magrath protocol)REG-HYPER-CVAD-R- Hyper-CVAD + Rituximab (CD20+) — alternating courses A/B, 8 cycles totalREG-MATRIX- MATRix (HD-Methotrexate + HD-Cytarabine + Thiotepa + Rituximab), 4 cyclesREG-MCL-INTENSIVE-RDHAP-AUTOSCT- Intensive 1L MCL: alternating R-CHOP / R-DHAP × 6 cycles + autoSCT consolidation + R main...REG-QUIZARTINIB-7-3- 7+3 + quizartinib induction + maintenance for FLT3-ITD+ AML 1LREG-RDHAP-BURKITT- R-DHAP (Rituximab + Dexamethasone + HD-Cytarabine + Cisplatin) × 2-3 cycles → ASCT/alloSC...